"In connection with the end-of-Phase 3 meeting held in March 2010 with FDA for NEO3-05, we also engaged FDA about amending the design of our third Lymphoseek Phase 3 clinical trial (NEO3-06) in order to specifically support claims aimed at sentinel node detection in subjects diagnosed with head and neck squamous cell carcinoma. Claims for sentinel lymph node mapping are intended to have a very specific focus distinct from claims for more generalized lymphatic mapping and anatomic delineation of lymphatic tissue. We began enrollment in the trial at clinical sites in the United States 2009 and are actively working to expand the trial, including the possible extension to clinical trial sites in Europe. The sample size calculations performed for NEO3-06 have modeled a total number of subjects of approximately 300 subjects for full completion of the study with a planned interim analysis to assess performance at approximately the halfway point. The potential interim analysis of the clinical data from the NEO3-06 study may occur by the end of 2011."
The NEO3-06 trial comparing lymphoseek to radical ALND in Head & Neck cancers will be a very interesting study imho. I think enrollment for Head & Neck is currently at 190 patients, so I suspect the interim analysis is near.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.